Does concomitant methotrexate have a clinically meaningful effect on vedolizumab pharmacokinetics in adults with ulcerative colitis or Crohn’s disease?

Population pharmacokinetic analyses suggest that concomitant methotrexate does not have a clinically meaningful effect on vedolizumab pharmacokinetics in adults with ulcerative colitis or Crohn’s disease, although no interaction studies have been performed.